Nucala — Cigna
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Initial criteria
- Age ≥ 18 years
- Has active, non-severe EGPA (vasculitis without life- or organ-threatening manifestations)
- Currently receiving a systemic corticosteroid and has been on therapy for a minimum of 4 weeks
- Has ONE of the following: blood eosinophil level ≥ 150 cells/µL within the previous 4 weeks OR blood eosinophil level ≥ 150 cells/µL prior to treatment with any monoclonal antibody therapy that may alter blood eosinophil levels
- Prescribed by or in consultation with an allergist, immunologist, pulmonologist, or rheumatologist
Reauthorization criteria
- Has already received at least 9 months of therapy with Nucala
- Responded to therapy as determined by the prescriber (e.g., reduced rate of relapse, corticosteroid dose reduction, reduced eosinophil levels)
Approval duration
initial 9 months, reauth 1 year